Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy

Personalis, Inc. (NASDAQ:PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can accurately identify triple negative breast cancer (TNBC) patients at high risk of relapse following neoadjuvant therapy (NAT).

Results from the PREDICT DNA and SCANDARE studies, presented at ASCO 2025, reveal that patients with detectable circulating tumor DNA (ctDNA) after NAT are up to 10 times more likely to experience recurrence than those who test negative.

A laboratory technician using high tech equipment to sequence cancer genomics.

Notably, ctDNA detection post-NAT proved a stronger predictor of relapse than traditional pathology, and patients who cleared ctDNA, even with residual disease, had excellent outcomes. Nearly half of post-NAT ctDNA detections were below 100 parts per million, underscoring the assay’s ultrasensitive performance.

A second study from Institut Curie confirmed that post-NAT ctDNA status is highly prognostic, with ctDNA-positive patients facing a 36-fold higher risk of distant relapse. Experts say these findings highlight the clinical need for ultrasensitive molecular residual disease (MRD) testing and could pave the way for ctDNA-guided decisions on additional therapy in early TNBC. Personalis, Inc. (NASDAQ:PSNL) aims to use this data to seek reimbursement coverage and optimize care for breast cancer patients.

Personalis, Inc. (NASDAQ:PSNL) is revolutionizing cancer care with cutting-edge personalized testing that supports active management throughout the patient journey. Using highly sensitive assays that profile both tumor and normal tissue alongside proprietary algorithms, they provide deep insights into cancer’s progression. Their solutions enable early detection of minimal residual disease (MRD) and recurrence, guide the selection of targeted therapies through comprehensive genomic profiling, and improve biomarker strategies for drug development. Personalis is headquartered in Fremont, California.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.